Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Sex-based differences in natural killer T cell-mediated protection against diet-induced steatohepatitis in Balb/c mice

  • Cuño-Gómiz, Carlos
  • Gregorio, Estefanía de
  • Tutusaus, Anna
  • Rider, Patricia
  • Andrés-Sánchez, Nuria
  • Colell Riera, Anna
  • Morales, Albert
  • Marí, Montserrat
Metabolic dysfunction-associated steatotic liver disease (MASLD) is prevalent in Western countries, evolving into metabolic dysfunction-associated steatohepatitis (MASH) with a sexual dimorphism. Fertile women exhibit lower MASLD risk than men, which diminishes post-menopause. While NKT-cell involvement in steatohepatitis is debated, discrepancies may stem from varied mouse strains used, predominantly C57BL6/J with Th1-dominant responses. Exploration of steatohepatitis, encompassing both genders, using Balb/c background, with Th2-dominant immune response, and CD1d-deficient mice in the Balb/c background (lacking Type I and Type II NKT cells) can clarify gender disparities and NKT-cell influence on MASH progression., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This study has been funded by Instituto de Salud Carlos III (ISCIII) through projects PI19/01410 and PI22/00475 to M.M., and co-funded by the European Union “ERDF A way of making Europe”; CIBEREHD and CIBERNED; grant numbers PID2021-123564OB-I00 to A.M and grant PID2022-143279OB-I00 to A.C. funded by MCIN/AEI/ 0.13039/501100011033 and by “ERDF A way of making Europe”. AGAUR, grant number 2021_SGR_00490 to A.C.; Fundació la Marató de TV3 to A.M.; and CERCA Programme/Generalitat de Catalunya., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Induction of the Inflammasome Pathway by Tyrosine Kinase Inhibitors Provides an Actionable Therapeutic Target for Hepatocellular Carcinoma

  • Tutusaus, Anna
  • Sanduzzi-Zamparelli, Marco
  • Boix, Loreto
  • Rider, Patricia
  • Subías, Silvia
  • García de Frutos, Pablo
  • Colell Riera, Anna
  • Marí, Montserrat
  • Reig, Maria
  • Morales, Albert
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)., Simple Summary: In the past decade, tyrosine kinase inhibitors sorafenib and regorafenib have been standard treatments for advanced liver cancer. Previous studies have associated sorafenib with inflammasome activation, but its therapeutic role in patients has not been explored. Our study found that both treatments altered inflammasome-related gene expression, showing a similar transcriptomic pattern in a mouse model of liver cancer. In accordance with public databases, inflammasome genes are associated with a poorer prognosis in male liver cancer patients, without changes in females. Thus, we analyzed biopsies from hepatocellular carcinoma patients treated with sorafenib/regorafenib and confirmed inflammasome activation. In experimental models, inflammasome inhibition enhanced sorafenib effectiveness, demonstrating its potential to overcome therapy resistance and improve its efficacy for liver cancer treatment., Abstract: During the last decade, tyrosine kinase inhibitors (TKIs) sorafenib and regorafenib have been standard systemic treatments for advanced hepatocellular carcinoma (HCC). Previous data associated sorafenib with inflammasome activation. However, the role of the inflammasome in sorafenib and regorafenib signaling has not been described in liver cancer patients. For this purpose, we analyzed inflammasome-related transcriptomic changes in a murine HCC model. Our data confirmed inflammasome activation after both TKI treatments, sharing a similar pattern of increased gene expression. According to human database results, transcriptional increase of inflammasome genes is associated with poorer prognosis for male liver cancer patients, suggesting a sex-dependent role for inflammasome activation in HCC therapy. In biopsies of HCC and its surrounding tissue, we detected durable increases in the inflammasome activation pattern after sorafenib or regorafenib treatment in male patients. Further supporting its involvement in sorafenib action, inflammasome inhibition (MCC950) enhanced sorafenib anticancer activity in experimental HCC models, while no direct in vitro effect was observed in HCC cell lines. Moreover, activated human THP-1 macrophages released IL-1β after sorafenib administration, while 3D Hep3B spheres displayed increased tumor growth after IL-1β addition, pointing to the liver microenvironment as a key player in inflammasome action. In summary, our results unveil the inflammasome pathway as an actionable target in sorafenib or regorafenib therapy and associate an inflammasome signature in HCC and surrounding tissue with TKI administration. Therefore, targeting inflammasome activation, principally in male patients, could help to overcome sorafenib or regorafenib resistance and enhance the efficacy of TKI treatments in HCC., This research was funded by Instituto de Salud Carlos III (ISCIII) through project PI22/00475 to M.M., FI19/00222 to M.S.-Z. and PI18/0358 to M.R., and co-funded by the European Union “ERDF A way of making Europe”; CIBEREHD, CIBERCV, and CIBERNED; Ministerio de Ciencia, Innovación y Universidades: grant numbers PID2021-123564OB-I00 and PDC2023-145806-I00 to A.M/P.G.F. and PID2022-143279OB-I00 to A.C. funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”. AGAUR, grant number 2021_SGR_00490 to A.C.; Fundació la Marató de TV3 to A.M.; and CERCA Programme/Generalitat de Catalunya., Peer reviewed